Presented by Eric Jonasch, MD, The University of Texas MD Anderson Cancer Center, Houston, Texas.
J Natl Compr Canc Netw. 2017 May;15(5S):703-705. doi: 10.6004/jnccn.2017.0078.
In 2017, pazopanib and sunitinib remain the mainstays of frontline therapy for advanced renal cell carcinoma. Independent review of frontline cabozantinib therapy may alter standard of care for patients at intermediate and poor risk. Multiple agents show a survival advantage in the second-line setting, including nivolumab, cabozantinib, and combination lenvatinib and everolimus. Selection of subsequent therapy will depend on patient disease status, comorbidities, and resource availability.
2017 年，帕唑帕尼和舒尼替尼仍然是晚期肾细胞癌一线治疗的主要药物。卡博替尼一线治疗的独立审查可能会改变中危和高危患者的治疗标准。多种药物在二线治疗中显示出生存优势，包括纳武单抗、卡博替尼以及仑伐替尼联合依维莫司。后续治疗的选择将取决于患者的疾病状态、合并症和资源可用性。
